Rayens Emily, Ku Jennifer H, Sy Lina S, Qian Lei, Ackerson Bradley K, Luo Yi, Tubert Julia E, Lee Gina S, Modha Punam P, Park Yoonyoung, Sun Tianyu, Anderson Evan J, Tseng Hung Fu
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Division of Clinical Development, Moderna Inc, Cambridge, Massachusetts, USA.
Influenza Other Respir Viruses. 2024 Dec;18(12):e70025. doi: 10.1111/irv.70025.
This retrospective cohort study evaluated the comparative vaccine effectiveness (cVE) of licensed standard-dose cell-based versus egg-based influenza vaccines in preventing influenza hospitalization among adults 18-64 years during the 2022-2023 season. The cohort included eligible Kaiser Permanente Southern California members who received ≥ 1 dose of influenza vaccine (n = 848,334). The adjusted cVE against influenza hospitalization was -10.1% (95% CI: -49.8%, 37.8%) in the 18- to 49-year-old cohort. In the 50- to 64-year-old cohort, the adjusted cVE was 14.9% (-33.8%, 52.1%). Cell-based and egg-based influenza vaccines conferred comparable protection against influenza hospitalization in adults 18-64 years of age in the 2022-2023 season.
这项回顾性队列研究评估了2022-2023流感季期间，已获许可的标准剂量细胞培养流感疫苗与鸡蛋培养流感疫苗在预防18至64岁成年人因流感住院方面的相对疫苗效力（cVE）。该队列包括符合条件的南加州凯撒医疗集团成员，他们接种了≥1剂流感疫苗（n = 848,334）。在18至49岁队列中，针对流感住院的调整后cVE为-10.1%（95%置信区间：-49.8%，37.8%）。在50至64岁队列中，调整后cVE为14.9%（-33.8%，52.1%）。在2022-2023流感季，细胞培养流感疫苗和鸡蛋培养流感疫苗在预防18至64岁成年人因流感住院方面提供了相当的保护。
